| LRP1B Protein |
|---|
| Protein Name | LDL Receptor-Related Protein 1B |
| Gene | LRP1B |
| UniProt ID | Q9NZB4 |
| Category | Cell Surface Receptor |
| Path | /proteins/lrp1b-protein |
LRP1B (LDL Receptor-Related Protein 1B) is a member of the LDL receptor family, closely related to LRP1. It is a large endocytic receptor expressed predominantly in the brain and various tissues. LRP1B functions as a tumor suppressor and is implicated in Alzheimer's disease pathogenesis through its role in amyloid-beta clearance and neuronal signaling.
LRP1B is a large transmembrane protein with the following architecture:
¶ Extracellular Domain
- Ligand-binding repeats: 32-33 complement-type repeats that bind various ligands
- Epidermal growth factor (EGF) precursor homology domain: Contains EGF-like repeats and spacer regions
- O-linked sugar domain: Threonine/serine-rich region
¶ Transmembrane Domain
- Single pass transmembrane helix: Spans the plasma membrane
¶ Cytoplasmic Domain
- NPXY motifs: Two NPXY endocytosis signals in the cytoplasmic tail
- Other signaling motifs: Phosphorylation sites for signal transduction
The protein has a molecular weight of ~600 kDa, making it one of the largest cell surface receptors.
LRP1B functions as a scavenger receptor:
- Ligand internalization: Binds and internalizes various ligands including:
- Apolipoprotein E (apoE)
- Amyloid-beta (Aβ) peptides
- Alpha-2-macroglobulin
- Tissue-type plasminogen activator (tPA)
- Various other proteins
- Receptor recycling: Efficient recycling back to the cell surface
- Lysosomal targeting: Directs ligands for degradation
In the brain, LRP1B plays important roles:
- Amyloid-beta clearance: Mediates neuronal uptake and clearance of Aβ
- Synaptic function: Regulates synaptic plasticity and memory
- Axonal transport: Involved in intracellular trafficking
- Neuroprotection: Protective against toxic protein aggregates
LRP1B participates in multiple signaling pathways:
- MAPK/ERK signaling: Activation of proliferative pathways
- PI3K/Akt signaling: Cell survival pathways
- Wnt signaling: Cross-talk with developmental pathways
- Brain: High expression in neurons, particularly cortex and hippocampus
- Lung: Bronchial epithelium
- Testis: Germ cells
- Lower expression: Heart, kidney, liver
LRP1B has significant implications in AD pathogenesis:
-
Amyloid-beta metabolism
- Mediates neuronal clearance of Aβ40 and Aβ42
- Implicated in Aβ uptake and degradation
- Dysregulation contributes to amyloid plaque formation
-
Genetic associations
- LRP1B polymorphisms linked to late-onset AD risk
- Expression changes in AD brain tissue
- Interaction with APOE alleles
-
Therapeutic target
- LRP1B modulators being explored for AD treatment
- Gene therapy approaches under investigation
Emerging evidence suggests roles in PD:
- May interact with alpha-synuclein clearance pathways
- Expression altered in PD substantia nigra
- Potential neuroprotective functions
LRP1B functions as a tumor suppressor:
- Frequent deletions: Lost in various cancers (lung, bladder, breast)
- Growth suppression: Overexpression inhibits tumor growth
- Metastasis: Role in cancer cell migration
LRP1B is closely related to LRP1 and shares many functions:
- Compensation: Can compensate for LRP1 loss in some contexts
- Differential ligand binding: Somewhat different ligand specificity
- Co-expression: Often expressed in same cell types
- Cooperative functions: May work together in amyloid clearance
- LRP1B agonists: Enhance Aβ clearance
- Gene therapy: Increase LRP1B expression
- Small molecule modulators: Target receptor function
- Tumor suppressor restoration: Reactivate LRP1B expression
- Synthetic lethality: Target LRP1B-deficient tumors
- Knockout mice: embryonic lethal in some backgrounds
- Conditional knockouts: Brain-specific deletion
- Transgenic models: Overexpression studies
- Humanized models: Expressing human LRP1B
- LRP1B: a tumor suppressor and Alzheimer's disease gene (2019)
- LRP1B in amyloid-beta clearance (2020)
- LDL receptor family in neurodegeneration (2021)
- LRP1 and LRP1B in Alzheimer's disease (2018)
- Receptor-mediated Aβ clearance (2022)
- LRP1B mutations in cancer (2019)